Literature DB >> 6326150

Inhibition of tissue damage by the arachidonate lipoxygenase inhibitor BW755C.

G A Higgs, K G Mugridge, S Moncada, J R Vane.   

Abstract

The effects of three anti-inflammatory drugs, which interfere with arachidonic acid transformation by three different enzymes, have been compared by using a simple model of tissue damage and foreign body rejection. In groups of control rats, subcutaneously implanted polyester sponges were rejected after a mean of 12 days. Indomethacin, which selectively inhibits prostaglandin synthesis, did not significantly change time to rejection but BW755C (3-amino-1-[m-(trifluoromethyl) phenyl]-2-pyrazoline), which is a dual inhibitor of prostaglandin and leukotriene synthesis, prolonged time to rejection to a mean of 22 days. The anti-inflammatory steroid dexamethasone, which reduces arachidonic acid metabolism by stimulating the formation of a phospholipase inhibitor, prolonged time to sponge rejection as BW755C did. Treatment with BW755C or dexamethasone was also accompanied by a reduction in total leukocyte numbers in inflammatory exudates collected at 1-14 days, whereas indomethacin increased leukocyte migration on days 1 and 2 and had no effect at later times. These results suggest that the inhibition of the leukotriene-forming lipoxygenase suppresses leukocyte activation and that this leads to a reduced rate of tissue damage in experimental inflammation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6326150      PMCID: PMC345178          DOI: 10.1073/pnas.81.9.2890

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  14 in total

1.  A new approach to anti-inflammatory drugs.

Authors:  G A Higgs; R J Flower; J R Vane
Journal:  Biochem Pharmacol       Date:  1979-06-15       Impact factor: 5.858

2.  The salvage of ischaemic myocardium by BW755C in anaesthetised dogs.

Authors:  K M Mullane; S Moncada
Journal:  Prostaglandins       Date:  1982-08

3.  Leukotriene B4, an inflammatory mediator in gout.

Authors:  S A Rae; E M Davidson; M J Smith
Journal:  Lancet       Date:  1982-11-20       Impact factor: 79.321

4.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes.

Authors:  A W Ford-Hutchinson; M A Bray; M V Doig; M E Shipley; M J Smith
Journal:  Nature       Date:  1980-07-17       Impact factor: 49.962

5.  Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis.

Authors:  L B Klickstein; C Shapleigh; E J Goetzl
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

6.  The effects of non-steroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation.

Authors:  G A Higgs; K E Eakins; K G Mugridge; S Moncada; J R Vane
Journal:  Eur J Pharmacol       Date:  1980-08-22       Impact factor: 4.432

7.  The effects of BW755C and other anti-inflammatory drugs on eicosanoid concentrations and leukocyte accumulation in experimentally-induced acute inflammation.

Authors:  J A Salmon; P M Simmons; S Moncada
Journal:  J Pharm Pharmacol       Date:  1983-12       Impact factor: 3.765

8.  Inhibition of arachidonic acid cyclo-oxygenase and lipoxygenase activities of leukocytes by indomethacin and compound BW755C.

Authors:  R W Randall; K E Eakins; G A Higgs; J A Salmon; J E Tateson
Journal:  Agents Actions       Date:  1980-12

9.  A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids.

Authors:  F Hirata; E Schiffmann; K Venkatasubramanian; D Salomon; J Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

10.  The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs).

Authors:  E J Goetzl; W C Pickett
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

View more
  7 in total

1.  The effects of drugs on leucocyte changes following the injection of antigen into the peritoneal cavities of actively sensitised rats.

Authors:  B A Spicer; S M Laycock; H Smith
Journal:  Agents Actions       Date:  1986-03

2.  Pharmacological investigation of acute cellular accumulation in immunological air pouch inflammation.

Authors:  P Hambleton; P Miller
Journal:  Agents Actions       Date:  1989-08

3.  Leukotrienes in disease. Implications for drug development.

Authors:  G A Higgs; S Moncada
Journal:  Drugs       Date:  1985-07       Impact factor: 9.546

4.  Anti-inflammatory pharmacology and mechanism of the orally active capsaicin analogs, NE-19550 and NE-28345.

Authors:  L M Brand; K L Skare; M E Loomans; H H Reller; R J Schwen; D A Lade; R L Bohne; C S Maddin; D P Moorehead; R Fanelli
Journal:  Agents Actions       Date:  1990-11

5.  Antagonism of leukotriene receptors and administration of a 5-lipoxygenase inhibitor do not affect hypoxic vasoconstriction.

Authors:  H M Thomas; M S Sourour; D Lopez; S H Foster
Journal:  Lung       Date:  1989       Impact factor: 2.584

6.  Macrolide antibiotics as antiinflammatory agents: roxithromycin in an unexpected role.

Authors:  C Agen; R Danesi; C Blandizzi; M Costa; B Stacchini; P Favini; M Del Tacca
Journal:  Agents Actions       Date:  1993-01

Review 7.  Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.

Authors:  J Martel-Pelletier; D Lajeunesse; P Reboul; J-P Pelletier
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.